Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
FAQ
How many Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings are available on StockTitan?
StockTitan tracks 134 SEC filings for Kiniksa Pharmaceuticals International, plc (KNSA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Kiniksa Pharmaceuticals International, plc (KNSA)?
The most recent SEC filing for Kiniksa Pharmaceuticals International, plc (KNSA) was filed on July 14, 2025.